Stoke prepares for IND, IPO with $90M series B

Stoke Therapeutics Inc. (Bedford, Mass.) is eyeing an IPO next half after raising $90 million in a series B round on Oct. 23 from a slew of new investors.

The company's Targeted Augmentation of Nuclear Gene Output (TANGO) platform, in-licensed from Cold Spring Harbor Laboratory and the University of Southampton, identifies intronic motifs associated with non-productive mRNA splicing and discovers antisense oligonucleotides (ASOs) that bind to splicing factor binding sites on the pre-mRNAs to induce normal splicing (see "Stoking Protein Production")...